Pharsight

Jelmyto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9040074 UROGEN PHARMA Material and method for treating internal cavities
Jan, 2031

(7 years from now)

US9950069 UROGEN PHARMA Material and method for treating internal cavities
Jan, 2031

(7 years from now)

Jelmyto is owned by Urogen Pharma.

Jelmyto contains Mitomycin.

Jelmyto has a total of 2 drug patents out of which 0 drug patents have expired.

Jelmyto was authorised for market use on 15 April, 2020.

Jelmyto is available in powder;pyelocalyceal dosage forms.

The generics of Jelmyto are possible to be released after 20 January, 2031.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 15, 2027
New Product (NP) Apr 15, 2023

Drugs and Companies using MITOMYCIN ingredient

Market Authorisation Date: 15 April, 2020

Treatment: NA

Dosage: POWDER;PYELOCALYCEAL

More Information on Dosage

JELMYTO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic